In July of last year Bayer agreed to $94 million for rights of torazolid in all markets except North America and Europe. That was before the recent study showing comparable results with better dosing schedule and shorter treatment coarse than linezolid. After the recent plummet in share price the rights to market torazolid in Europe and North America are worth well more than the market cap of this company ($140 million). My biggest concern is someone coming in and buying this company on the cheap. Their lead product is certain to be a billion dollar drug but this company may get taken over for <$6. Lets see some insider buying or some announcements to jack up the price a little. To have a drug this big only 1-2 years away from showtime is phenomenal. No debt, plenty of cash to finance until marketability. What am I missing here??
Listened to a few investor's conferences this morning and I believe lack of interest at this time is driving the stock price. Company plans to complete second phase 3 study by end of 2012 and hopefully bring to market by 2014. They have hired pfizer's VP of marketing that responsible for marketing Zyvox and also are looking into European partnerships and evaluating offers. A good long-term investment and from my perspective, the CEO seems to be doing all the right things to bring this drug to market and compete in the gram positive antibiotic market.
I agree with the potential. Great studies and blockbuster drug on the horizon. There was a recent dilution at a price of $5.25/share. Volume is always low and there hasn't been any major news lately, so maybe lost interest?